21 - 23 April 2027Moscow, Crocus Expo, Pavilion 3, Hall 14
RU
In August 2024, Türkiye quietly crossed a threshold most countries haven't reached: more than 100 licensed genetic diagnosis centres can now test for all 8,000 known rare genetic conditions using kits developed and produced domestically.
In August 2024, Türkiye quietly crossed a threshold most countries haven't reached: more than 100 licensed genetic diagnosis centres can now test for all 8,000 known rare genetic conditions using kits developed and produced domestically.
Blood samples that once had to be flown to Europe for analysis can now be processed at home, faster and at lower cost, for a population where more than 7 million people live with a rare disease. That single shift says more about the direction of Turkish diagnostics than any market forecast.
The country isn't just buying next-generation sequencing (NGS) technology; it's building the capacity to run the whole workflow itself.
Türkiye's diagnostic labs market was valued at USD 4.48 billion in 2024 and is projected to reach USD 6.82 billion by 2030, a 7.2% compound annual growth rate, according to TechSci Research. Pathology and molecular testing, which includes genetic and NGS-based diagnostics, is the fastest-growing category in that forecast, driven by rising cancer rates and Türkiye's well-documented burden of inherited disease.
That is a genuinely fast pace of clinical adoption. But test volume alone doesn't equal capability. A lab that doubles its sequencing throughput without rethinking how results move from instrument to interpretation to clinician hasn't modernised; it has just built a longer queue.
This is the part of the "digital transformation" conversation that gets skipped: NGS generates the raw data, but AI and connected data systems decide whether that data reaches a doctor in a usable form, on time.
The more interesting shift over the past year hasn't been in the sequencers themselves; it's in what happens after sequencing.
In November 2025, at the Association for Molecular Pathology's annual meeting in Boston, Complete Genomics and SOPHiA GENETICS announced a partnership to integrate SOPHiA GENETICS' AI-driven MSK-IMPACT and MSK-ACCESS oncology assays directly into Complete Genomics' new sequencing platform, creating a single sample-to-report pipeline for cancer labs.
As Rob Tarbox, VP of Product and Marketing at Complete Genomics, put it: "Pairing MSK-IMPACT and MSK-ACCESS powered with SOPHiA DDM with our DNBSEQ-T1+ platform creates a powerful and accessible solution for laboratories looking to scale high-quality cancer genomic profiling."
That's a telling signal. The industry's growth is increasingly concentrated in interpretation, not just generation. Genomic data diagnostics is projected to be the fastest-growing NGS application through 2031, according to MarketsandMarkets, largely because clinical demand has shifted from research settings to routine patient testing.
For Turkish labs, this matters more than it might elsewhere. The country's genetic testing capacity has expanded fast on the diagnostic side, but the bioinformatics and data-interpretation layer hasn't always kept pace with instrument purchases.
The labs pulling ahead aren't necessarily the ones buying the newest sequencer; they're the ones building the surrounding workflow so that whatever instrument they already own works harder and more reliably.
This isn't happening in a vacuum. Türkiye's national genome and bioinformatics initiative, run through the Türkiye Biotechnology Institute, has sequenced more than 500 whole genomes to date, feeding a growing reference database for precision medicine.
The country now counts over 100 genetic diagnostic laboratories across public hospitals and private centres, increasingly running NGS-based panels for prenatal screening, hereditary conditions, and oncology, according to the U.S. Commercial Service's latest healthcare market guide. For once, public investment and private clinical demand are pulling in the same direction.
Here's the point worth making plainly: the constraint in Turkish diagnostics right now is rarely sequencing capacity. It's everything downstream of it: instrument connectivity, standardised data formats, and workflows that don't rely on someone manually re-entering results into a second system.
Labs evaluating their next investment get a higher return from automated laboratory research solutions that reduce hands-on time and strengthen data integrity than from a marginally faster sequencer on top of the same manual bottlenecks.
The same logic applies to hardware decisions. Generally, the labs seeing the clearest gains are pairing genomic testing with advanced lab instruments chosen for how well they integrate with existing data systems, not just their raw specifications.
These aren't abstract questions; procurement teams, lab directors, and instrument suppliers are actively negotiating them right now, increasingly in person.
Analitika Expo brings that conversation into one room: recent editions have drawn thousands of laboratory specialists and 200-plus exhibiting companies from across Russia, the CIS, and beyond, a scale that reflects how much of this decision-making still happens face to face, where buyers can see integration and connectivity demonstrated rather than described in a spec sheet.
Türkiye's diagnostic labs don't have a technology problem. They have an integration problem, and it's solvable. Suppliers with automation, connectivity, or AI-interpretation tools built for exactly this gap should submit an exhibit enquiry to reach the labs and procurement teams actively building their next-generation workflows.